BioIVT enhances its website to facilitate drug and diagnostic R&D

BioIVT has added advanced tissue, biofluid and cell search and e-commerce capabilities to its website, which is enabling customers to mine its biospecimen repository and related clinical database using artificial intelligence (AI) and machine learning (ML) applications to advance scientific knowledge of different diseases.  

According to BioIVT, more than 140,000 blocks from its ASTERAND Human Tissue Biorepository are available, together with more than 50,000 individual biofluid and cell lots that can be searched by diagnosis, sample format, and matrix. The results can be further filtered by specimen-specific features, such as tumour percent, grade, and stage for tissue; next-generation sequencing, enzyme activity or human leucocyte antigen annotation; medications taken and social demographics.  

Also featured in each clinical dataset are the donor’s diagnosis and status, co-morbidities, treatments (past and present), medications, and cause of death if available. Biospecimens from donors with cancer include the AJCC/UICC stage, and histological data, such as the percentage of tumour, normal and necrotic tissue. 

Dr Courtney Noah, Senior Vice President, Marketing and Client Services at BioIVT, said: “This new website functionality will allow them to conduct detailed, multifaceted searches of our BioIVT Biorepository, keep track of their new orders and previous purchases, and obtain copies of important documentation.” 

“We want to use BioIVT’s extensive, well-characterised, high quality tissue repository and accompanying clinical database to help progress customers’ drug discovery and diagnostics research. We already have hematoxylin and eosin (H&E) images and clinical data from more than one million biospecimens, collected over 30 years, in our ASTERAND Human Tissue Repository,” said Cathie Miller, Senior Director of Product Marketing, Personalised Medicine at BioIVT. “In addition, our biobank consistently contains hundreds of thousands of disease-state and normal biospecimens that are collected by our global network of more than 350 donor institutions. Every one of our biospecimens is supplied with more than 200 data points, including patient outcomes.” 

Image credit: Glenn Carstens

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free